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Objectives: Observational studies have questioned the effectiveness of perioperative
calcium channel blockers but failed to correct for selection biases. We therefore
performed a prospective observational cohort study of the effects of calcium channel
blockers on cardiac surgical mortality. A propensity score technique was used for
risk adjustment.
Methods: We identified 6619 patients who underwent nontransplant cardiac surgery
at the Toronto General Hospital (Toronto, Ontario, Canada) between May 1999 and
December 2001. Propensity scores for calcium channel blocker use were con-
structed for the entire sample and for the subgroup (n  5222) that underwent
coronary artery bypass grafting. The calcium channel blocker adjusted odds ratio for
in-hospital mortality after cardiac surgery was determined by using multiple logistic
regression and propensity matched-pairs analyses. A subgroup analysis was per-
formed for patients who underwent coronary artery bypass grafting: the calcium
channel blocker adjusted odds ratio for mortality was determined by using propen-
sity score matched-pairs analyses.
Results: Calcium channel blockers were associated with significantly reduced car-
diac surgical mortality after adjustment with both multiple logistic regression (odds
ratio, 0.56; 95% confidence interval, 0.33-0.94; P  .028) and propensity score
matched-pairs analyses (odds ratio, 0.56; 95% confidence interval, 0.32-0.98; P 
.042). Calcium channel blockers were also associated with reduced mortality (odds
ratio, 0.48; 95% confidence interval, 0.23-0.98; P  .044) among patients who
underwent coronary artery bypass grafting.
Conclusions: After adjustment for baseline differences, calcium channel blockers
were associated with significantly reduced mortality after cardiac surgery. This
benefit also extends to the subgroup that underwent coronary artery bypass grafting.
A large randomized controlled trial of perioperative calcium channel blockers is
therefore warranted.
The role of calcium channel blockers (CCBs) in cardiac surgery iscontroversial. Prior observational studies concluded that CCBs didnot reduce mortality1 or myocardial ischemia.2,3 In contrast, a recentmeta-analysis of randomized controlled trials (RCTs) found thatCCBs significantly reduced perioperative myocardial infarction (MI)and ischemia during cardiac surgery;4 however, the study was un-
derpowered to determine effects on mortality.
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CCBs have multiple benefits that explain the findings of
the meta-analysis. They improve balance between myocar-
dial oxygen supply and demand through negative chrono-
tropic, negative inotropic, afterload-reducing, and coronary
vasodilatatory properties. Imbalance between myocardial
oxygen supply and demand might cause ischemia and MI.5
CCB-mediated vasodilatation might reduce coronary artery
bypass graft (CABG) spasm, another cause of postoperative
ischemia. Nondihydropyridine CCBs have also been shown
to prevent supraventricular tachyarrhythmias in both animal
studies6 and the recent meta-analysis.4 They might therefore
reduce postoperative atrial fibrillation, which is associated
with neurocognitive dysfunction7 and prolonged hospital-
ization.8
The cause of the discrepancies between RCTs and ob-
servational studies might be inadequate risk adjustment for
important selection biases. Patients receiving CCBs are
likely to be older, with more chronic obstructive pulmonary
disease, peripheral vascular disease, and diabetes mellitus.
These systemic diseases increase cardiac surgical mortali-
ty.9 Furthermore, they reduce the likelihood of receiving
-blockers,10 which reduce mortality after CABG sur-
gery.11 Indeed, only 30% of patients who receive CCBs
after MI will receive -blockers concurrently.10 Further-
more, CCB users might have more severe coronary artery
disease that failed symptomatic control with -blockers
alone. Failure to adjust for these selection biases will pre-
vent identification of the treatment effects of CCBs.
We therefore undertook a prospective observational co-
hort study of cardiac surgical patients, aiming to determine
the effects of CCBs on in-hospital mortality while adjusting
for selection biases with propensity score techniques.12
Methods
Patient Population and Data Sources
Preoperative, intraoperative, and postoperative information for in-
dividuals undergoing cardiac surgery at the Toronto General Hos-
pital, University Health Network (Toronto, Ontario, Canada), was
prospectively collected in cardiac surgery and anesthesia registries,
with the approval of the institutional research ethics board. These
databases have been previously described.13,14 The databases doc-
ument CCB and -blocker use in the preoperative period but not in
the intraoperative or postoperative periods. All cardiac surgical
patients at the Toronto General Hospital routinely receive their last
preoperative dose of cardiac medication on the morning of the
operation.
The study sample consisted of individuals who underwent
nontransplant cardiac surgical procedures between May 1, 1999,
and December 31, 2001. A total of 6635 individuals underwent
eligible procedures. We excluded 16 (0.2%) patients with missing
preoperative medication data. Ninety-two (1.4%) patients had
missing data in elements aside from preoperative medications. An
unknown left ventricular ejection fraction was considered equal to
a normal ejection fraction (60%), a previously used approach15
recommended by Pierpont and associates.16 Missing values for
dichotomous variables were assigned the most frequent value,
whereas continuous variables were assigned the median value, as
previously described.11 Reanalysis after exclusion of patients with
missing data did not materially alter the results.
General Analysis Issues
All analyses were performed with SAS Version 8.20 software
(SAS Institute, Cary, NC).
Propensity Score Development
Given that CCB therapy assignment was nonrandom, confounding
and selection biases were accounted for through a propensity score
for CCB use. The rationale and methods underlying the use of
propensity scores for proposed causal exposure variables have
been previously described.17 Multiple logistic regression18 was
used to construct a propensity score for preoperative CCB use,
without regard for outcome. We developed a full nonparsimonious
model, including 26 covariates and 18 first-order interactions (Ta-
ble 1). This model had an area under the receiver operating
characteristic (ROC) curve of 0.73.
Multiple Logistic Regression Risk Adjustment
The effects of CCBs and -blockers on in-hospital mortality were
determined by using multiple logistic regression. Treatment effects
were adjusted by using the following covariates: year, age, sex, left
ventricular ejection fraction (60%, 40%-60%, 20%-40%, and
20%), procedure (CABG, single-valve surgery, and complex
procedures), prior cardiac surgery, timing of operation, triple-
vessel coronary disease (stenoses 70% in 3 major coronary
arteries), left main coronary artery disease (stenosis 50%), MI
within 30 days, Canadian Cardiovascular Society class IV angina,
preoperative intra-aortic balloon pump support, diabetes mellitus,
peripheral vascular disease, cerebrovascular disease, and chronic
obstructive pulmonary disease. Operation timing was graded as
follows: elective, semiurgent (cannot leave hospital without sur-
gical intervention), urgent (surgical intervention required within 72
hours of presentation), and emergency (surgical intervention re-
quired within 12 hours of presentation).
Three models were generated. The first model consisted of the
risk-adjustment covariates alone. The second model consisted of
the risk-adjustment covariates, CCB use, and -blocker use. The
third model consisted of the risk-adjustment covariates, CCB use,
-blocker use, and propensity score. We calculated adjusted odds
ratios (ORs) and 95% confidence intervals (CIs) for CCB and
-blocker use in the 2 latter regression models.
Combined CCB and -blocker use might represent a harmful
interaction given their combined negative inotropic effects. We
therefore tested the statistical significance of adding an interaction
term between CCBs and -blockers in the third regression model.
The models’ discrimination and calibration were determined by
using ROC curve areas and Hosmer-Lemeshow goodness-of-fit
statistics, respectively.18
Propensity Score Matched-Pairs Analysis
To determine the robustness of the results from model-based
risk-adjustment techniques, we also calculated the treatment ef-
fects of CCBs by using a matched-pairs analysis. Using an SAS
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macro (available at www2.sas.com/proceedings/sugi26/p214-
26.pdf), we matched CCB users to unique control subjects by
using their propensity scores.* We attempted to match each CCB
user to a non-CCB user with a propensity score identical to 5
digits. If this was not possible, we attempted 4-, 3-, 2-, and 1-digit
matches. Once this threshold was passed, that specific CCB user
was excluded.
Conditional logistic regression was used to determine the ef-
fects of CCBs on mortality and several postoperative complica-
tions: dialysis, low cardiac output state, permanent pacemaker
insertion, reoperation, and major bleeding. Low cardiac output
state was defined as the need for intra-aortic balloon pump support
or inotropic medication (dopamine in excess of 4 g · kg1 ·
min1, dobutamine, milrinone, or epinephrine) for at least 30
minutes to maintain systolic blood pressure of greater than 90 mm
Hg and cardiac output of greater than 2.2 L · min1 · m2.13 Major
bleeding was defined as a requirement for more than 10 units of
blood during the operative period, chest tube drainage of greater
than 2400 mL over 24 hours, or reoperation for significant bleed-
ing.19
Subgroup Analyses
CCBs might have different effects among individuals with signif-
icant coronary artery disease. We therefore performed a subgroup
analysis for patients who underwent CABG with and without any
concurrent procedures. This subgroup consisted of 5222 (78.9%)
patients.
A propensity score for CCB use within this subgroup was
developed by using multiple logistic regression. We developed a
full nonparsimonious model, including 24 covariates and 16 first-
order interactions; these variables are available from the authors.
The ROC area for this model was 0.68. Matched pairs were
generated on the basis of propensity scores, as described above.
Conditional logistic regression modeling was used to determine
the effects of CCBs on mortality, dialysis, low cardiac output state,
permanent pacemaker insertion, reoperation, and major bleeding.
Sensitivity Analyses
Given that -blockers are associated with reduced mortality after
CABG,11 we carried out sensitivity analyses to determine whether
preoperative -blocker use affected the treatment effects of CCBs.
Patients who underwent CABG were further divided into 2 sub-
groups defined by whether they were or were not receiving
-blockers preoperatively. We used multiple logistic regression to
determine the adjusted effects of CCBs on mortality within each
subgroup. Although age, sex, and CCB use were forced into the
models, forward stepwise selection was used to identify other
covariates. We used stepwise selection because of the limited
statistical power of the subgroups. The covariates considered were
year, left ventricular ejection fraction, procedure other than
CABG, prior cardiac surgery, timing of operation, triple-vessel
coronary disease, left main coronary artery disease, MI within 30
* Parsons LS. Reducing bias in a propensity score matched-pair sample by
using greedy matching techniques. Presented at the 26th Meeting of SAS
Users’ Group International (SUGI 26); April 22-25, 2001; Long Beach,
Calif.
TABLE 1. Propensity score model for entire study sample
Covariates Interaction terms
Year Year  procedure type
Age Age  sex
Sex Age  left ventricular ejection fraction
Body surface area Age  timing of operation
New York Heart Association class Age  procedure type
Triple-vessel coronary artery disease Age  repeat operation
Left main coronary artery disease Left ventricular ejection fraction  timing of operation
Left ventricular ejection fraction Left ventricular ejection fraction  procedure type
MI within 30 d Left ventricular ejection fraction  repeat operation
Cerebrovascular disease Left ventricular ejection fraction  hypertension
Peripheral vascular disease Procedure type  triple-vessel coronary artery disease
Prior PTCA Procedure type  -blocker use
Positive stress test result Procedure type  inhaled bronchodilator use
Prior thrombolysis MI within 30 days  repeat operation
Diabetes mellitus Peripheral vascular disease  New York Heart Association class
Hypercholesterolemia Positive stress test result  procedure type
Hypertension Positive stress test result  prior PTCA
Current smoker Positive stress test result  left ventricular ejection fraction
Preoperative hemoglobin concentration
Preoperative serum creatinine concentration
-Blocker use
Inhaled bronchodilator use
Angiotensin-converting enzyme inhibitor use
Repeat operation
Timing of operation
Procedure type
PTCA, Percutaneous transluminal coronary angioplasty.
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days, Canadian Cardiovascular Society class IV angina, preoper-
ative intra-aortic balloon pump support, diabetes mellitus, periph-
eral vascular disease, cerebrovascular disease, and chronic ob-
structive pulmonary disease. A P value of less than .05 was
required for inclusion.
Results
Patient Characteristics
The study sample consisted of 6619 patients; 31.7% (n 
2097) were receiving CCBs preoperatively. The prevalence
of CCB use decreased from 35% in 1999 to 29% in 2001.
The in-hospital mortality rate was 1.8% (n  117). The
patients’ baseline characteristics are summarized in Table 2.
Renal dysfunction was defined as a preoperative creatinine
concentration of greater than 130 mol/L, which is associ-
ated with increased perioperative mortality and morbidity.20
Multiple Logistic Regression Risk Adjustment
The model consisting of the risk-adjustment covariates
alone had an ROC area of 0.85, with good calibration (2
6.22, P  .62). CCBs were associated with significant
reductions in mortality both before (OR, 0.55; 95% CI,
0.33-0.92; P  .022) and after (OR, 0.56; 95% CI, 0.33-
0.94; P  .028) adjustment for propensity score (Table 3).
-Blockers were also associated with significant reductions
in mortality in both models (Table 3). The interaction term
between CCB use and -blocker use was statistically non-
significant (P  .59).
The risk-adjusted model without a propensity score had
an ROC area of 0.86, with good calibration (2 5.75, P
.68). The model with a propensity score had similar dis-
crimination (ROC area of 0.86) and calibration (2  7.16,
P  .52).
TABLE 2. Baseline characteristics of study sample
Variables
Entire study sample Propensity-matched pairs
CCB
(n  2097)
No CCB
(n  4522) P value
CCB
(n  1890)
No CCB
(n  1890) P value
Demographic
Age, y (mean) 65 60 .0001 65 64 .51
Body surface area, m2 (mean) 1.92 1.90 .005 1.92 1.91 .73
Female sex (%) 25.9 26.9 .38 24.8 26.1 .35
Preoperative cardiac status (%)
New York Heart Association class IV 49.9 46.3 .0064 50.3 51.9 .35
Triple-vessel disease 54.4 39.7 .0001 53.2 52.2 .56
Left main coronary artery disease 18.0 14.7 .0007 17.7 17.9 .86
Left ventricular ejection fraction
60% 42.8 43.8 .0003 41.4 42.8 .77
40%-60% 39.3 35.1 39.5 38.6
20%-40% 16.0 17.8 16.9 16.7
20% 2.0 3.4 2.2 1.9
Congestive heart failure 15.4 23.0 .0001 16.4 17.7 .30
MI within 30 d 13.8 16.7 .003 14.9 14.9 .93
Preoperative intra-aortic balloon pump 1.6 2.4 .035 1.7 2.1 .40
Cerebrovascular disease 10.1 8.6 .054 9.5 10.6 .26
Peripheral vascular disease 17.6 11.3 .0001 16.1 16.7 .60
Comorbid disease (%)
Diabetes mellitus 30.9 22.9 .0001 30.1 30.1 .97
Renal dysfunction 9.6 7.9 .023 9.6 8.3 .17
Preoperative dialysis 0.86 0.73 .58 0.9 1.0 .73
Chronic obstructive pulmonary disease 5.5 3.5 .0001 5.0 4.4 .44
Preoperative medications (%)
-Blockers 67.5 62.6 .0001 70.2 70.1 .94
Angiotensin-converting enzyme inhibitors 41.7 44.5 .029 43.3 43.4 .97
Operative details (%)
Repeat operation 6.7 8.8 .0036 6.4 6.3 .89
Surgical status
Elective 58.2 56.7 .0001 56.8 55.6 .89
Semi-urgent 36.1 34.0 36.8 37.8
Urgent 5.1 6.2 5.6 5.8
Emergency 0.7 3.1 0.8 0.9
Procedure type
CABG only 81.3 61.3 .0001 80.6 80.7 .89
Single valve 5.0 14.6 5.5 6.1
Complex 13.1 24.2 13.9 13.2
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Propensity Score Matched-Pairs Analysis
Of the 2097 CCB users in the entire study sample, 90% (n
 1890) were matched to unique control subjects. These
matched pairs were well balanced for all known covariates
(Table 2). The in-hospital mortality rate was 1.4% (n 53).
Within the matched-pairs sample, CCBs were associated
with significant reductions in mortality (OR, 0.56; 95% CI,
0.32-0.98; P  .042; Table 4). CCBs were not associated
with statistically significant increases in postoperative com-
plications (Table 4).
Subgroup Analyses
The baseline characteristics of the 5222 patients undergoing
CABG are summarized in Table 5; 37.1% (n  1935) were
receiving CCBs preoperatively. The in-hospital mortality
rate was 1.5% (n  79).
Of the 1935 CCB users within the CABG subgroup, 89%
(n  1726) were matched to unique control subjects. These
matched pairs were well balanced for all known covariates
(Table 5). The in-hospital mortality rate for matched pairs
was 1.1% (n  38).
Among the matched pairs, CCBs were associated with
significant reductions in mortality (OR, 0.48; 95% CI, 0.23-
0.98; P  .044; Table 6). CCBs were not associated with
statistically significant increases in postoperative complica-
tions (Table 6).
Sensitivity Analyses
The CABG subgroup that received -blockers preopera-
tively consisted of 3900 patients, of which 35% (n  1362)
were receiving CCBs. The effect of CCBs on mortality
among patients receiving -blockers (Table 7) was similar
in magnitude to that determined by matched-pairs analyses
(Table 6).
The CABG subgroup that was not receiving -blockers
preoperatively numbered 1322, of which 43% (n  573)
were receiving CCBs. The effect of CCBs on mortality
within this subgroup (Table 6) was also similar to that
determined by matched-pairs analyses (Table 7).
Discussion
To our knowledge, this is the largest observational study to
examine the effects of CCBs on perioperative mortality
after cardiac surgery. Approximately 32% of patients were
receiving CCBs preoperatively, with use gradually declin-
ing from 1999 to 2001. Multiple selection biases determined
CCB use, including differences in age, sex, cardiac disease,
systemic disease, and preoperative medications. After ad-
justing for selection biases, CCBs were associated with
significantly reduced in-hospital mortality among patients
undergoing cardiac surgery, including the subgroup under-
going CABG.
In addition to demonstrating that CCBs were associated
with reduced mortality, this study also found that CCBs
were free of major side effects. Although CCBs are negative
chronotropes, negative inotropes, and platelet inhibitors,21
we found no evidence that they increased the incidence of
related postoperative complications. Furthermore, the ben-
efits of CCBs appeared to be consistent, regardless of
whether patients were or were not receiving -blockers
preoperatively.
Comparison With Prior Studies
Our results contradict prior observational studies and sup-
port a recent meta-analysis.4 Two early studies2,3 looked
only at the effects of CCBs on myocardial ischemia, a
surrogate outcome, and did not use risk-adjustment tech-
niques. More recently, Weightman and colleagues1 found
that CCBs had no effect on mortality, whereas -blockers
exerted a significant beneficial effect. However, their mul-
tiple logistic regression analysis had less statistical power
than ours. The power of logistic regression models depends
in large part on the number of outcome events.22 There were
only 53 deaths in the study by Weightman and colleagues.
In contrast, we used more rigorous statistical risk-adjust-
ment techniques in a sample with 119 deaths.
The recent meta-analysis of preoperative, intraoperative,
and postoperative (first 48 hours) CCB use was underpow-
ered to demonstrate significant changes in perioperative
mortality.4 However, CCBs were associated with trends
toward decreased mortality among patients undergoing
TABLE 3. Adjusted effects of CCBs and -blockers
Medication
OR for mortality
(95% CI) P Value
Model without propensity score
CCB 0.55 (0.33-0.92) .022
-Blocker 0.52 (0.34-0.79) .0026
Model with propensity score
CCB 0.56 (0.33-0.94) .028
-Blocker 0.51 (0.33-0.79) .0023
TABLE 4. Outcomes for propensity score matched pairs
Outcomes CCB No CCB OR 95% CI
Patient no. 1890 1890
In-hospital mortality (%) 1.01 1.80 0.56 0.32-0.98 (P.042)
Morbidity (%)
Dialysis 1.01 1.32 0.76 0.42-1.38 (P .37)
Low-output state 4.50 4.29 1.05 0.77-1.45 (P .75)
Permanent pacemaker
insertion
2.96 2.54 1.17 0.79-1.73 (P .43)
Repeat operation 5.71 5.03 1.15 0.86-1.53 (P .34)
Major bleeding 4.55 4.50 1.01 0.75-1.37 (P .94)
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CABG (OR, 0.66; 95% CI, 0.26-1.70; P  .4). The simi-
larity in treatment effects observed in the meta-analysis and
this observational study strengthens arguments that CCBs
have important mortality benefits during cardiac surgery.
Our results argue against concerns that CCBs increase
perioperative mortality, as suggested by Legault and co-
workers.23 Their RCT of nimodipine use during valve sur-
gery was terminated early because of an excess of deaths in
the CCB arm, largely caused by excessive bleeding. How-
ever, these patients all underwent hypothermic cardiopul-
monary bypass. The latter inhibits platelet function,24
whereas its effects on perioperative blood loss are
TABLE 5. Subgroup who underwent CABG
Variables
Entire subgroup Propensity-matched pairs
CCB
(n  1935)
No CCB
(n  3287) P value
CCB
(n  1726)
No CCB
(n  1726) P value
Demographic
Age, y (mean) 66 63 .0001 65 65 .41
Body, m2 surface area (mean) 1.92 1.91 .42 1.92 1.92 .76
Female sex (%) 24.3 21.2 .0098 23.9 22.0 .17
Preoperative cardiac status (%)
New York Heart Association class IV 52.2 56.5 .0026 53.1 53.0 .97
Triple-vessel disease 58.9 54.6 .0030 58.6 58.5 .97
Left main coronary artery disease 19.4 20.1 .54 19.3 19.0 .86
Left ventricular ejection fraction
60% 36.9 36.9 .0001 41.0 40.4 .97
40%-60% 39.6 38.5 39.6 40.4
20%-40% 16.5 21.3 17.4 17.2
20% 2.0 3.4 2.0 2.0
Congestive heart failure 12.3 16.5 .0001 12.7 13.9 .29
MI within 30 d 14.9 22.5 .0001 16.3 15.8 .68
Preoperative intra-aortic balloon pump 1.7 3.1 .0021 1.8 2.1 .54
Cerebrovascular disease 10.2 8.6 .055 9.8 9.8 1.00
Peripheral vascular disease 18.7 14.8 .0002 18.4 17.7 .62
Comorbid disease (%)
Diabetes mellitus 32.6 29.2 .011 32.2 30.2 .23
Renal dysfunction 9.7 8.2 .062 9.2 8.2 .33
Preoperative dialysis 0.9 0.9 .86 0.9 0.9 1.00
Chronic obstructive pulmonary disease 5.8 4.2 .0063 5.1 4.7 .58
Preoperative medications (%)
-Blockers 70.4 77.2 .0001 74.9 75.0 .94
Angiotensin-converting enzyme inhibitors 42.5 50.4 .0001 44.2 44.2 .97
Operative details (%)
Repeat operation 5.3 4.2 .054 4.6 4.8 .87
Surgical status
Elective 56.4 48.9 .0001 54.4 53.9 .61
Semi-urgent 37.6 41.5 39.5 40.4
Urgent 5.3 7.7 5.6 4.9
Emergency 0.7 1.9 0.6 0.8
Other procedure with CABG 11.2 15.7 12.2 12.6 .72
TABLE 6. Outcomes for propensity matched patients undergoing CABG
Outcomes CCB No CCB OR 95% CI
Patient number 1726 1726
In-hospital mortality (%) 0.75 1.45 0.48 0.23-0.98 (P.044)
Morbidity (%)
Dialysis 1.04 1.04 1.00 0.52-1.92 (P1.00)
Low-output state 4.69 4.63 1.01 0.74-1.39 (P .94)
Permanent pacemaker insertion 2.20 1.91 1.15 0.72-1.84 (P .55)
Repeat operation 5.21 4.58 1.15 0.84-1.56 (P .61)
Major bleeding 3.94 4.29 0.92 0.65-1.28 (P .61)
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mixed.24,25 Furthermore, only 46% received aminocaproic
acid, an antifibrinolytic agent that reduces blood loss during
cardiac surgery by 30% to 40%.26 By comparison, patients
undergoing cardiac surgery at our hospital do not undergo
hypothermic cardiopulmonary bypass and routinely receive
antifibrinolytic agents. In contrast to the study by Legault
and coworkers,23 our analyses found no association between
CCB use and major bleeding, thereby supporting a recent
review that concluded that most of the clinical data linking
CCBs and bleeding points against an increased risk.27
Study Limitations
Although this study used a variety of statistical methods to
correct for confounders and selection biases, it is an obser-
vational study. Hence interpretation of results from this
study should be limited to associations between variables of
interest. No causal inferences should be drawn. Further-
more, cardiac surgical outcomes are confounded by a mul-
titude of factors. The constraints of feasibility limit data
collection in observational studies of this design; therefore
all factors that determined preoperative CCB use might not
have been collected. Although propensity scores reduce bias
caused by observed covariates, they cannot remove con-
founding from these unobserved covariates. Only an RCT is
able to do the latter.
Our analyses did not have sufficient power to determine
whether CCBs benefit the subgroup receiving preoperative
-blockers. Nonetheless, our results suggest that the 2 med-
ications have additive benefits, without any negative inter-
actions. The logistic regression interaction term between
CCBs and -blockers was statistically nonsignificant. In
addition, sensitivity analyses showed that preoperative
-blocker use did not affect the magnitude of benefits of
CCBs among patients undergoing CABG.
Our data set did not allow us to determine the effects of
different classes of CCBs: benzothiazepines (eg, diltiazem),
phenylalkyamines (eg, verapamil), and dihydropyridines
(eg, nifedipine and amlodipine). This is important given that
dihydropyridines have been associated with increased mor-
tality in nonsurgical studies.28 In addition, we were not able
to determine whether CCB therapy was continued through-
out the immediate postoperative period. More than 50% of
patients previously receiving CCBs might not receive them
postoperatively.29 The findings of the above meta-analysis,4
however, suggest that ongoing CCB use intraoperatively
and postoperatively would likely improve perioperative out-
comes as well.
Finally, this study might have been affected by site
confounding, given that our results reflect the effects of
CCBs in a single tertiary care institution. Furthermore, the
1.8% perioperative mortality rate seen in this study contrasts
with the 3.1% rate reported in a recent North American
population-based study of CABG surgery.11 The generaliz-
ability of our results to other hospitals will therefore require
further study. It is nonetheless reassuring that CCBs have
benefits even when baseline operative risks are relatively
low.
Clinical Implications
CCBs remain relatively underused in cardiac surgical prac-
tice, largely because of the results of prior observational
studies.1-3 This observational study, using a larger sample
size and more sophisticated risk-adjustment techniques,
suggests instead that preoperative CCBs are associated with
significant reductions in perioperative mortality. In light of
a meta-analysis showing that intraoperative and postopera-
tive CCB use significantly reduces MI and ischemia,4 there
is now strong justification for prospectively investigating
perioperative CCB use among cardiac surgical patients.
The most appropriate method for determining their effi-
cacy is a large simple RCT, a feasible option given that
750,000 individuals annually undergo cardiac surgical pro-
cedures in the United States alone.30 We would further
suggest that this trial should target individuals undergoing
CABG, the subgroup most likely to benefit from perioper-
ative CCBs.
We acknowledge the superb data collection and management of
Susan Collins at the University Health Network.
TABLE 7. Sensitivity analyses examining whether preoperative -blockers influence the treatment effects of CCBs on
CABG mortality
-Blocker
use
CCB OR for mortality
(95% CI) Included covariates Regression model characteristics
Yes 0.52 (0.25-1.09) Age, sex, left ventricular ejection fraction, timing
of operation, procedure other than CABG,
prior cardiac surgery
Area under ROC curve  0.83
Hosmer-Lemeshow statistic 2  5.18 (P  .74)
No 0.47 (0.18-1.19) Age, sex, left ventricular ejection fraction, timing
of operation, procedure other than CABG
Area under ROC curve  0.83
Hosmer-Lemeshow statistic 2  2.64 (P  .92)
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